Drug Patents Expiring in 2034

1. List of Abilify Maintena Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10525057 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Mar, 2034

(11 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 28 February, 2013

Treatment: Maintenance monotherapy treatment of bipolar 1 disorder; Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; Treatment of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

How can I launch a generic of ABILIFY MAINTENA KIT before it's patent expiration?
More Information on Dosage

2. List of Abraxane drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9511046 ABRAXIS BIOSCIENCE Methods of treating pancreatic cancer
Jan, 2034

(10 years from now)

US9511046

(Pediatric)

ABRAXIS BIOSCIENCE Methods of treating pancreatic cancer
Jul, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
M Dec 6, 2022
Pediatric Exclusivity (PED) Jun 6, 2023

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Treatment: Treatment of pancreatic cancer

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of ABRAXANE before it's patent expiration?
More Information on Dosage

3. List of Adempas drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10662188 BAYER HLTHCARE Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate
Feb, 2034

(11 years from now)

US11203593 BAYER HLTHCARE Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
Feb, 2034

(11 years from now)

Drugs and Companies using RIOCIGUAT ingredient

Market Authorisation Date: 08 October, 2013

Treatment: Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (cteph), (who group 4) after surgical treatment, or inoperable cteph, to improve exercise capacity and who functional class; Treatment of adults with pulmonary hypertension (pah), (who group 1), to improve exercise capacity, who functional class and to delay clinical worsening

Dosage: TABLET;ORAL

How can I launch a generic of ADEMPAS before it's patent expiration?
More Information on Dosage

4. List of Airduo Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9066957 TEVA PHARM Dry powder inhaler
Oct, 2034

(11 years from now)

US9415008 TEVA PHARM Dry powder inhaler
Oct, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
M Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: Treatment of asthma

Dosage: POWDER;INHALATION

More Information on Dosage

5. List of Alkindi Sprinkle drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649280 ETON Composition comprising hydrocortisone
May, 2034

(11 years from now)

Drugs and Companies using HYDROCORTISONE ingredient

Market Authorisation Date: 29 September, 2020

Treatment: Treatment of adrenal insufficiency

Dosage: GRANULE;ORAL

More Information on Dosage

6. List of Alunbrig drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9611283 TAKEDA PHARMS USA Methods for inhibiting cell proliferation in ALK-driven cancers
Apr, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 28, 2022
Orphan Drug Exclusivity (ODE) May 22, 2027
New Indication (I) May 22, 2023

Drugs and Companies using BRIGATINIB ingredient

NCE-1 date: April, 2021

Market Authorisation Date: 28 April, 2017

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Dosage: TABLET;ORAL

More Information on Dosage

7. List of Arikayce Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566234 INSMED INC Systems for treating pulmonary infections
Jan, 2034

(10 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 28, 2025
Generating Antibiotic Incentives Now (GAIN) Sep 28, 2030

Drugs and Companies using AMIKACIN SULFATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

More Information on Dosage

8. List of Aubagio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186346 SANOFI AVENTIS US Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
Feb, 2034

(11 years from now)

US9186346

(Pediatric)

SANOFI AVENTIS US Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
Aug, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
M Apr 30, 2024
Pediatric Exclusivity (PED) Oct 30, 2024

Drugs and Companies using TERIFLUNOMIDE ingredient

Market Authorisation Date: 12 September, 2012

Treatment: Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction by limiting the rosuvastatin dose to no more than 10mg and/or administering about half the normal dose

Dosage: TABLET;ORAL

How can I launch a generic of AUBAGIO before it's patent expiration?
More Information on Dosage

9. List of Austedo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9550780

(Pediatric)

TEVA BRANDED PHARM Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(11 years from now)

US9233959

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(11 years from now)

US9296739

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(11 years from now)

US9814708

(Pediatric)

TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Mar, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 3, 2024
New Chemical Entity Exclusivity (NCE) Apr 3, 2022
M Jun 24, 2024
Pediatric Exclusivity (PED) Oct 3, 2024

Drugs and Companies using DEUTETRABENAZINE ingredient

NCE-1 date: October, 2023

Market Authorisation Date: 03 April, 2017

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of AUSTEDO before it's patent expiration?
More Information on Dosage

10. List of Auvelity drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11517542 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11524007 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10463634 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11517543 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11141388 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11213521 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11129826 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11123343 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10966974 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10512643 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US10105361 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11524008 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11497721 AXSOME NA
Nov, 2034

(11 years from now)

US11478468 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11510918 AXSOME NA
Nov, 2034

(11 years from now)

US9968568 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US10092560 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11311534 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10105327 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11382874 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11364233 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9457025 AXSOME Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(11 years from now)

US10058518 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9278095 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9867819 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US9168234 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9861595 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US9700553 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11357744 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11344544 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9486450 AXSOME Hydroxybupropion and related compounds as modulators of drug plasma levels
Nov, 2034

(11 years from now)

US9474731 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US9375429 AXSOME Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
Nov, 2034

(11 years from now)

US9421176 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US9408815 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9763932 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US9205083 AXSOME Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
Nov, 2034

(11 years from now)

US9707191 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US10898453 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11433067 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9700528 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US9370513 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US9457023 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US9238032 AXSOME Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(11 years from now)

US11096937 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11298352 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10966941 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11298351 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11090300 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10894047 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10064857 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11291665 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11291638 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10786469 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11253492 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10881657 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10874663 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10799497 AXSOME Combination of dextromethorphan and bupropion for treating depression
Nov, 2034

(11 years from now)

US11058648 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11273133 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10864209 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10806710 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10881624 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US10786496 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11020389 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11185515 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10945973 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11285146 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11285118 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10596167 AXSOME Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(11 years from now)

US11439636 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US9314462 AXSOME Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US9198905 AXSOME Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11426401 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11426370 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11419867 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10772850 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11273134 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11253491 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11234946 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10548857 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11229640 AXSOME Combination of dextromethorphan and bupropion for treating depression
Nov, 2034

(11 years from now)

US10874665 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10933034 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10251879 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10092561 AXSOME Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Nov, 2034

(11 years from now)

US10894046 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11191739 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10874664 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10080727 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

US11197839 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11147808 AXSOME Method of decreasing the fluctuation index of dextromethorphan
Nov, 2034

(11 years from now)

US11207281 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US11141416 AXSOME Bupropion as a modulator of drug activity
Nov, 2034

(11 years from now)

US10780066 AXSOME Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Nov, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Aug 18, 2025

Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient

Market Authorisation Date: 18 August, 2022

Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

11. List of Ayvakit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9944651 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(11 years from now)

US9200002 BLUEPRINT MEDICINES Compositions useful for treating disorders related to KIT
Oct, 2034

(11 years from now)

US9994575 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 9, 2025
New Indication (I) Jun 16, 2024
Orphan Drug Exclusivity (ODE) Jan 9, 2027

Drugs and Companies using AVAPRITINIB ingredient

NCE-1 date: January, 2024

Market Authorisation Date: 09 January, 2020

Treatment: Treatment of unresectable or metastatic gastrointestinal stromal tumor (gist) harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation; Treatment of advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with an associated hematological neoplasm (sm-ahn), and mast cell leukemia (mcl)

Dosage: TABLET;ORAL

More Information on Dosage

12. List of Barhemsys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9084765 ACACIA Use of amisulpride as an anti-emetic
Feb, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 26, 2025

Drugs and Companies using AMISULPRIDE ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 26 February, 2020

Treatment: Prevention of post-operative nausea and vomiting; Treatment of post-operative nausea and vomiting

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

13. List of Bosulif drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103497 PF PRISM CV Treatment of imatinib resistant leukemia
Feb, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 19, 2024

Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient

Market Authorisation Date: 04 September, 2012

Treatment: A method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at 949t>c; A method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at f317l

Dosage: TABLET;ORAL

How can I launch a generic of BOSULIF before it's patent expiration?
More Information on Dosage

14. List of Brukinsa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9447106 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators
Apr, 2034

(11 years from now)

US11142528 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(11 years from now)

US10570139 BEIGENE Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Apr, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 14, 2024
Orphan Drug Exclusivity (ODE) Sep 14, 2028
New Indication (I) Sep 14, 2024

Drugs and Companies using ZANUBRUTINIB ingredient

NCE-1 date: November, 2023

Market Authorisation Date: 14 November, 2019

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; For the treatment of patients with waldenstrom's macroglobulinemia; Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen

Dosage: CAPSULE;ORAL

More Information on Dosage

15. List of Camzyos drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9181200 BRISTOL Pyrimidinedione compounds
Jun, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9585883 BRISTOL Pyrimidinedione compounds
Jun, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 28, 2027

Drugs and Companies using MAVACAMTEN ingredient

NCE-1 date: April, 2026

Market Authorisation Date: 28 April, 2022

Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms

Dosage: CAPSULE;ORAL

More Information on Dosage

16. List of Caplyta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11026951 INTRA-CELLULAR Methods of treating bipolar disorder
Dec, 2034

(11 years from now)

US10960009 INTRA-CELLULAR Methods of treating schizophrenia and depression
Dec, 2034

(11 years from now)

US9956227 INTRA-CELLULAR Method for the treatment of residual symptoms of schizophrenia
Dec, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 20, 2024
New Indication (I) Dec 17, 2024

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

NCE-1 date: December, 2023

Market Authorisation Date: 20 December, 2019

Treatment: Treatment of bipolar i disorder, bipolar ii disorder, or bipolar depression; Treatment of schizophrenia; Treatment of schizophrenia with improvement in residual symptoms of schizophrenia

Dosage: CAPSULE;ORAL

More Information on Dosage

17. List of Cibinqo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9035074 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(11 years from now)

US9545405 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549929 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 14, 2027

Drugs and Companies using ABROCITINIB ingredient

NCE-1 date: January, 2026

Market Authorisation Date: 14 January, 2022

Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable

Dosage: TABLET;ORAL

More Information on Dosage

18. List of Clenpiq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10624879 FERRING PHARMS INC Liquid pharmaceutical composition
Jun, 2034

(11 years from now)

US11191753 FERRING PHARMS INC Liquid pharmaceutical composition
Jun, 2034

(11 years from now)

US9827231 FERRING PHARMS INC Liquid pharmaceutical composition
Jun, 2034

(11 years from now)

Drugs and Companies using CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE ingredient

Market Authorisation Date: 28 November, 2017

Treatment: For cleansing of the colon as a preparation for colonoscopy; For cleansing the large intestine as a preparation for colonoscopy

Dosage: SOLUTION;ORAL

How can I launch a generic of CLENPIQ before it's patent expiration?
More Information on Dosage

19. List of Contrave drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10828294 NALPROPION Compositions and methods for weight loss in at risk patient populations
Jul, 2034

(11 years from now)

US10231964 NALPROPION Compositions and methods for weight loss in at risk patient populations
Jul, 2034

(11 years from now)

US10835527 NALPROPION Compositions and methods for reducing major adverse cardiovascular events
Jul, 2034

(11 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: For chronic weight management for treating overweight or obesity

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of CONTRAVE before it's patent expiration?
More Information on Dosage

20. List of Cosela drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9487530 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(11 years from now)

US10085992 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(11 years from now)

US10966984 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(11 years from now)

US11040042 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 12, 2026

Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient

NCE-1 date: February, 2025

Market Authorisation Date: 12 February, 2021

Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung cancer; A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a topotecan-containing regimen for extensive- stage small cell lung cancer; A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a carboplatin and etoposide-containing regimen for extensive-stage small cell lung cancer

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

21. List of Cotellic drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11087354 GENENTECH INC Combination therapies
Jun, 2034

(11 years from now)

US11087354

(Pediatric)

GENENTECH INC Combination therapies
Dec, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 10, 2022
New Indication (I) Oct 28, 2025
M Jul 28, 2025
Pediatric Exclusivity (PED) Jan 28, 2026

Drugs and Companies using COBIMETINIB FUMARATE ingredient

Market Authorisation Date: 10 November, 2015

Treatment: Method of using cobimetinib for the treatment of melanoma

Dosage: TABLET;ORAL

More Information on Dosage

22. List of Dexycu Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028965 EYEPOINT PHARMS Use of sustained release dexamethasone in post-cataract surgery inflammation
May, 2034

(11 years from now)

US10159683 EYEPOINT PHARMS Use of sustained release dexamethasone in post-cataract surgery inflammation
May, 2034

(11 years from now)

US10022502 EYEPOINT PHARMS Dose guides for injection syringe
Jun, 2034

(11 years from now)

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 09 February, 2018

Treatment: Treatment of postoperative inflammation

Dosage: SUSPENSION;INTRAOCULAR

More Information on Dosage

23. List of Dificid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9808530 CUBIST PHARMS LLC Composition of tiacumicin compounds
May, 2034

(11 years from now)

US9808530

(Pediatric)

CUBIST PHARMS LLC Composition of tiacumicin compounds
Nov, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Jan 24, 2023
Orphan Drug Exclusivity (ODE) Jan 24, 2027
Pediatric Exclusivity (PED) Jul 24, 2023

Drugs and Companies using FIDAXOMICIN ingredient

Market Authorisation Date: 24 January, 2020

Treatment: NA

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of DIFICID before it's patent expiration?
More Information on Dosage

24. List of Dilaudid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248229 FRESENIUS KABI USA Packaging system for oxygen-sensitive drugs
Mar, 2034

(11 years from now)

Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 11 January, 1984

Treatment: NA

Dosage: INJECTABLE;INJECTION

How can I launch a generic of DILAUDID before it's patent expiration?
More Information on Dosage

25. List of Doryx drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9511031 MAYNE PHARMA Controlled release doxycycline
Oct, 2034

(11 years from now)

US9295652 MAYNE PHARMA Controlled release doxycycline
Oct, 2034

(11 years from now)

US9446057 MAYNE PHARMA Controlled release doxycycline
Dec, 2034

(11 years from now)

Drugs and Companies using DOXYCYCLINE HYCLATE ingredient

Market Authorisation Date: 06 May, 2005

Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of DORYX before it's patent expiration?
More Information on Dosage

26. List of Durysta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9980974 ALLERGAN INC Prostamide-containing intraocular implants and methods of use thereof
Oct, 2034

(11 years from now)

US9492316 ALLERGAN INC Prostamide-containing intraocular implants and methods of use thereof
Oct, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 4, 2023

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage

27. List of Epclusa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10086011 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(11 years from now)

US11116783 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(11 years from now)

US9757406 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(11 years from now)

US9757406

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

US11116783

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

US10086011

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 10, 2028
New Strength (NS) Mar 19, 2023
M Apr 27, 2025
New Dosing Schedule (D) Nov 15, 2022
New Patient Population (NPP) Mar 19, 2023
Pediatric Exclusivity (PED) May 15, 2023

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Market Authorisation Date: 28 June, 2016

Treatment: For the treatment of hepatitis c

Dosage: TABLET;ORAL

More Information on Dosage

28. List of Epinephrine drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039728 BELCHER More potent and less toxic formulations of epinephrine and methods of medical use
Aug, 2034

(11 years from now)

US10004700 BELCHER More potent and less toxic formulations of epinephrine and methods of medical use
Aug, 2034

(11 years from now)

US9283197 BELCHER More potent and less toxic formulations of epinephrine and methods of medical use
Aug, 2034

(11 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 29 July, 2014

Treatment: Increasing mean arterial blood pressure in adult patients with hypotension associated with septic shock; Emergency treatment of allergic reactions (type 1), including anaphylaxis; A method of treating allergic reaction, anaphylaxis, anaphylactic shock, or combination thereof by an injection of at least one dosage of the injectable liquid pharmaceutical; Emergency treatment of allergic reactions (type i), including anaphylaxis; Induction and maintenance of mydriasis during intraocular surgery

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS; SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

How can I launch a generic of EPINEPHRINE before it's patent expiration?
More Information on Dosage

29. List of Evomela drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10040872 ACROTECH Alkylated cyclodextrin compositions and processes for preparing and using the same
Jan, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 10, 2023

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Market Authorisation Date: 10 March, 2016

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of EVOMELA before it's patent expiration?
More Information on Dosage

30. List of Evzio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9517307 KALEO INC Devices and methods for delivering opioid antagonists including formulations for naloxone
Jul, 2034

(11 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: Use of an auto injector to administer naloxone hcl

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

31. List of Evzio (autoinjector) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9517307 KALEO INC Devices and methods for delivering opioid antagonists including formulations for naloxone
Jul, 2034

(11 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: Use of an auto injector to administer naloxone hcl

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

32. List of Exondys 51 drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9506058 SAREPTA THERAPS INC Compositions for treating muscular dystrophy
Mar, 2034

(11 years from now)

US10364431 SAREPTA THERAPS INC Compositions for treating muscular dystrophy
Mar, 2034

(11 years from now)

US10337003 SAREPTA THERAPS INC Compositions for treating muscular dystrophy
Mar, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 19, 2023

Drugs and Companies using ETEPLIRSEN ingredient

Market Authorisation Date: 19 September, 2016

Treatment: Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Restoring an mrna reading frame to induce dystrophin protein production in patients having a mutation of the dmd gene that is amenable to exon 51 skipping

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

33. List of Firdapse drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10793893 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
May, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 28, 2023
Orphan Drug Exclusivity (ODE) Nov 28, 2025
New Patient Population (NPP) Sep 29, 2025

Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 28 November, 2018

Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine

Dosage: TABLET;ORAL

More Information on Dosage

34. List of Fulvestrant drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9833459 FRESENIUS KABI USA Fulvestrant formulations
Feb, 2034

(11 years from now)

US10188663 FRESENIUS KABI USA Fulvestrant formulations
Feb, 2034

(11 years from now)

US9271990 FRESENIUS KABI USA Fulvestrant formulations
May, 2034

(11 years from now)

Drugs and Companies using FULVESTRANT ingredient

Market Authorisation Date: 20 May, 2019

Treatment: Treatment of hormone receptor positive advanced breast cancer in postmenopausal women

Dosage: SOLUTION;INTRAMUSCULAR

More Information on Dosage

35. List of Furoscix drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9884039 SCPHARMACEUTICALS Pharmaceutical formulations for subcutaneous administration of furosemide
Apr, 2034

(11 years from now)

US10272064 SCPHARMACEUTICALS Pharmaceutical formulations for subcutaneous administration of furosemide
Apr, 2034

(11 years from now)

US11433044 SCPHARMACEUTICALS Pharmaceutical formulations for subcutaneous administration of furosemide
Apr, 2034

(11 years from now)

Drugs and Companies using FUROSEMIDE ingredient

Market Authorisation Date: 07 October, 2022

Treatment: Use of a liquid formulation comprising furosemide to treat congestion due to fluid overload (edema) in adults with nyha class ii/iii chronic heart failure

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

36. List of Ganzyk-rtu drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9486530 EXELA PHARMA Ganciclovir compositions and related methods
Sep, 2034

(11 years from now)

Drugs and Companies using GANCICLOVIR ingredient

Market Authorisation Date: 17 February, 2017

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

37. List of Giapreza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11096983 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(11 years from now)

US10028995 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(11 years from now)

US9220745 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(11 years from now)

US10493124 LA JOLLA PHARMA Angiotensin II alone or in combination for the treatment of hypotension
Dec, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 21, 2022

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 21 December, 2017

Treatment: Treating distributive shock with angiotensin ii; Treating septic shock with angiotensin ii; Maintaining mean arterial pressure of about 65 mmhg or above with about 1 ng/kg/min to about 40 ng/kg/min angiotensin ii in hypotensive patients treated with vasopressin or a vasopressin analogue and reducing vasopressin or vasopressin analogue use; Maintaining mean arterial pressure of about 65 mmhg or higher with angiotensin ii in shock patients treated with catecholamines and reducing catecholamine use; Treating high output shock with angiotensin ii by increasing mean arterial pressure in patients treated with catecholamines and reducing catecholamine use; Treating low blood pressure with angiotensin ii at an initial rate of about 20 ng/kg/min and titrating down to achieve and/or maintain a map of about 65 mm hg or above

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of GIAPREZA before it's patent expiration?
More Information on Dosage

38. List of Givlaari drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11028392 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Oct, 2034

(11 years from now)

US10119143 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Oct, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 20, 2024
Orphan Drug Exclusivity (ODE) Nov 20, 2026

Drugs and Companies using GIVOSIRAN SODIUM ingredient

NCE-1 date: November, 2023

Market Authorisation Date: 20 November, 2019

Treatment: Treatment of acute hepatic porphyria

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

39. List of Glyxambi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
M Jul 3, 2022

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

Market Authorisation Date: 30 January, 2015

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (30 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin

Dosage: TABLET;ORAL

How can I launch a generic of GLYXAMBI before it's patent expiration?
More Information on Dosage

40. List of Gocovri drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10646456 ADAMAS PHARMA Methods of administering amantadine
Jun, 2034

(11 years from now)

US10154971 ADAMAS PHARMA Methods of administering amantadine
Dec, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 24, 2024

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 August, 2017

Treatment: Treatment of dyskinesia, decreasing off time, and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia and decreasing off time in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of GOCOVRI before it's patent expiration?
More Information on Dosage

41. List of Harvoni drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10039779 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039779

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Dosing Schedule (D) Nov 15, 2022
Orphan Drug Exclusivity (ODE) Apr 7, 2024
Pediatric Exclusivity (PED) Oct 7, 2024

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Market Authorisation Date: 10 October, 2014

Treatment: For the treatment of genotype 1, 4, 5 or 6 chronic hepatitis c virus (hcv) infection; For the treatment of hepatitis c; For treatment-naive genotype 1 patients with chronic hepatitis c virus (hcv) infection for a duration of 8-weeks

Dosage: TABLET;ORAL

More Information on Dosage

42. List of Hetlioz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9730910 VANDA PHARMS INC Treatment of circadian rhythm disorders
May, 2034

(11 years from now)

US10610511 VANDA PHARMS INC Method of treatment
Oct, 2034

(11 years from now)

US11141400 VANDA PHARMS INC Method of treatment
Oct, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 1, 2023
Orphan Drug Exclusivity (ODE) Dec 1, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 31 January, 2014

Treatment: Treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; Treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food

Dosage: CAPSULE;ORAL

How can I launch a generic of HETLIOZ before it's patent expiration?
More Information on Dosage

43. List of Hetlioz Lq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9730910 VANDA PHARMS INC Treatment of circadian rhythm disorders
May, 2034

(11 years from now)

US11141400 VANDA PHARMS INC Method of treatment
Oct, 2034

(11 years from now)

US10610511 VANDA PHARMS INC Method of treatment
Oct, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Dec 1, 2023
Orphan Drug Exclusivity (ODE) Dec 1, 2027

Drugs and Companies using TASIMELTEON ingredient

Market Authorisation Date: 01 December, 2020

Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food

Dosage: SUSPENSION;ORAL

More Information on Dosage

44. List of Ibrance drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10723730 PFIZER Solid forms of a selective CDK4/6 inhibitor
Feb, 2034

(11 years from now)

Drugs and Companies using PALBOCICLIB ingredient

Market Authorisation Date: 01 November, 2019

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of IBRANCE before it's patent expiration?
More Information on Dosage

45. List of Idhifa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10093654 CELGENE CORP Therapeutically active compounds and their methods of use
Aug, 2034

(11 years from now)

US9738625 CELGENE CORP Therapeutically active compounds and their methods of use
Aug, 2034

(11 years from now)

US9732062 CELGENE CORP Therapeutically active compounds and their methods of use
Sep, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 1, 2024
New Chemical Entity Exclusivity (NCE) Aug 1, 2022

Drugs and Companies using ENASIDENIB MESYLATE ingredient

NCE-1 date: August, 2021

Market Authorisation Date: 01 August, 2017

Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation

Dosage: TABLET;ORAL

More Information on Dosage

46. List of Imbruvica drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9540382

(Pediatric)

PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Feb, 2034

(11 years from now)

US9296753

(Pediatric)

PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Apr, 2034

(11 years from now)

US10463668 PHARMACYCLICS INC Methods of treating and preventing graft versus host disease
Oct, 2034

(11 years from now)

US10695350 PHARMACYCLICS INC Methods of treating and preventing graft versus host disease
Oct, 2034

(11 years from now)

US9795604 PHARMACYCLICS INC Methods of treating and preventing graft versus host disease
Oct, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
M Jan 25, 2022
New Patient Population (NPP) Aug 24, 2025
Orphan Drug Exclusivity (ODE) Aug 2, 2024
Pediatric Exclusivity (PED) Feb 24, 2026

Drugs and Companies using IBRUTINIB ingredient

Market Authorisation Date: 13 November, 2013

Treatment: Treatment of refractory chronic graft-versus-host disease; Treatment of chronic graft versus host disease refractory to systemic therapy; Treatment of pediatric patients age 1 year and older with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy

Dosage: CAPSULE;ORAL

How can I launch a generic of IMBRUVICA before it's patent expiration?
More Information on Dosage

47. List of Imcivree drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11129869 RHYTHM Pharmaceutical compositions
Jul, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 25, 2027
New Chemical Entity Exclusivity (NCE) Nov 25, 2025
New Indication (I) Jun 16, 2025

Drugs and Companies using SETMELANOTIDE ACETATE ingredient

NCE-1 date: November, 2024

Market Authorisation Date: 25 November, 2020

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

48. List of Imvexxy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11266661 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Feb, 2034

(11 years from now)

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 29 May, 2018

Treatment: Treatment of dyspareunia; Treatment of a symptom of vulvar and vaginal atrophy

Dosage: INSERT;VAGINAL

How can I launch a generic of IMVEXXY before it's patent expiration?
More Information on Dosage

49. List of Inomax drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9279794 MALLINCKRODT HOSP Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide
Feb, 2034

(11 years from now)

US9279794

(Pediatric)

MALLINCKRODT HOSP Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide
Aug, 2034

(11 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 23 December, 1999

Treatment: A method of providing nitric oxide therapy to a patient by compensating long-term sensitivity drift of electrochemical gas sensors used in systems for delivering therapeutic nitric oxide to a patient

Dosage: GAS;INHALATION

How can I launch a generic of INOMAX before it's patent expiration?
More Information on Dosage

50. List of Jadenu drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9283209 NOVARTIS PHARMS CORP Oral formulations of deferasirox
Nov, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
M Jul 23, 2023

Drugs and Companies using DEFERASIROX ingredient

Market Authorisation Date: 30 March, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of JADENU before it's patent expiration?
More Information on Dosage

51. List of Jardiance drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

US9949997 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
May, 2034

(11 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Aug 18, 2024
M Feb 24, 2025

Drugs and Companies using EMPAGLIFLOZIN ingredient

Market Authorisation Date: 01 August, 2014

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (30 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of reducing the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease by once daily administration of 10 mg or 25 mg of empagliflozin; Method for reducing the risk of cardiovascular death and hospitalization for heart failure in adults with type 2 diabetes mellitus and heart failure by once daily administration of empagliflozin; Method for reducing the risk of cardiovascular death plus hospitalization for heart failure in adults with type 2 diabetes mellitus, heart failure and reduced ejection fraction by once daily administration of empagliflozin

Dosage: TABLET;ORAL

How can I launch a generic of JARDIANCE before it's patent expiration?
More Information on Dosage

52. List of Jublia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10864274 BAUSCH Stabilized efinaconazole formulations
Oct, 2034

(11 years from now)

US9662394 BAUSCH Stabilized efinaconazole compositions
Oct, 2034

(11 years from now)

US10342875 BAUSCH Stabilized efinaconazole compositions
Oct, 2034

(11 years from now)

US10828293 BAUSCH Anti-infective methods, compositions, and devices
Oct, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Apr 27, 2023

Drugs and Companies using EFINACONAZOLE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: Antimycotic uses, specifically treatment of onychomycosis; Topical treatment of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes

Dosage: SOLUTION;TOPICAL

How can I launch a generic of JUBLIA before it's patent expiration?
More Information on Dosage

53. List of Kloxxado drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10722510 HIKMA Liquid naloxone spray
Aug, 2034

(11 years from now)

US10973814 HIKMA Liquid naloxone spray
Aug, 2034

(11 years from now)

US11135155 HIKMA Liquid naloxone spray
Aug, 2034

(11 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 29 April, 2021

Treatment: Use of naloxone for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients

Dosage: SPRAY;NASAL

More Information on Dosage

54. List of Leqvio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10125369 NOVARTIS PCSK9 iRNA compositions and methods of use thereof
Aug, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 22, 2026

Drugs and Companies using INCLISIRAN SODIUM ingredient

NCE-1 date: December, 2025

Market Authorisation Date: 22 December, 2021

Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

55. List of Liletta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028858 MEDICINES360 Intrauterine systems, IUD insertion devices, and related methods and kits therefor
Mar, 2034

(11 years from now)

Drugs and Companies using LEVONORGESTREL ingredient

Market Authorisation Date: 26 February, 2015

Treatment: A method for prevention of pregnancy

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage

56. List of Lonsurf drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10457666 TAIHO ONCOLOGY Stable crystal form of tipiracil hydrochloride and crystallization method for the same
Jun, 2034

(11 years from now)

US9527833 TAIHO ONCOLOGY Stable crystal form of tipiracil hydrochloride and crystallization method for the same
Jun, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Feb 22, 2022
Orphan Drug Exclusivity (ODE) Feb 22, 2026

Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient

Market Authorisation Date: 22 September, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of LONSURF before it's patent expiration?
More Information on Dosage

57. List of Loreev Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8999393 ALMATICA Sustained release formulations of lorazepam
Jan, 2034

(10 years from now)

Drugs and Companies using LORAZEPAM ingredient

Market Authorisation Date: 27 August, 2021

Treatment: Once daily treatment of anxiety disorder in adults

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

58. List of Luzu drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8980931 BAUSCH Method of evaluating pharmaceutical preparation containing luliconazole and index substance
Apr, 2034

(11 years from now)

Drugs and Companies using LULICONAZOLE ingredient

Market Authorisation Date: 14 November, 2013

Treatment: NA

Dosage: CREAM;TOPICAL

More Information on Dosage

59. List of Makena drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9789257 COVIS Needle assisted injection device having reduced trigger force
Feb, 2034

(11 years from now)

Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient

Market Authorisation Date: 03 February, 2011

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR; SOLUTION;SUBCUTANEOUS

How can I launch a generic of MAKENA before it's patent expiration?
More Information on Dosage

60. List of Mavyret drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10286029 ABBVIE INC Method for treating HCV
Mar, 2034

(11 years from now)

US11484534 ABBVIE INC Methods for treating HCV
Mar, 2034

(11 years from now)

US10286029

(Pediatric)

ABBVIE INC Method for treating HCV
Sep, 2034

(11 years from now)

US11484534

(Pediatric)

ABBVIE INC Methods for treating HCV
Sep, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 3, 2022
New Patient Population (NPP) Apr 30, 2022
Orphan Drug Exclusivity (ODE) Jun 10, 2028
New Dosing Schedule (D) Sep 26, 2022
M Apr 10, 2023
Pediatric Exclusivity (PED) Feb 3, 2023

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

NCE-1 date: February, 2022

Market Authorisation Date: 03 August, 2017

Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg

Dosage: TABLET;ORAL

More Information on Dosage

61. List of Morphine Sulfate drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248229 FRESENIUS KABI USA Packaging system for oxygen-sensitive drugs
Mar, 2034

(11 years from now)

US9192608 FRESENIUS KABI USA Morphine formulations
Mar, 2034

(11 years from now)

US9072781 FRESENIUS KABI USA Morphine formulations
Mar, 2034

(11 years from now)

Drugs and Companies using MORPHINE SULFATE ingredient

Market Authorisation Date: 30 October, 2013

Treatment: Management of chronic pain in patients requiring opioid analgesia; Treatment of pain

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS

More Information on Dosage

62. List of Natesto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11090312 ACERUS Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
Mar, 2034

(11 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 28 May, 2014

Treatment: Nasal administration of a testosterone gel to a patient to treat the patient for a condition associated with a deficiency or absence of endogenous testosterone

Dosage: GEL, METERED;NASAL

More Information on Dosage

63. List of Omidria drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9486406

(Pediatric)

RAYNER SURGICAL Stable preservative-free mydriatic and anti-inflammatory solutions for injection
Apr, 2034

(11 years from now)

US9066856

(Pediatric)

RAYNER SURGICAL Stable preservative-free mydriatic and anti-inflammatory solutions for injection
Apr, 2034

(11 years from now)

Drugs and Companies using KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 May, 2014

Treatment: NA

Dosage: SOLUTION;IRRIGATION

How can I launch a generic of OMIDRIA before it's patent expiration?
More Information on Dosage

64. List of Onzetra Xsail drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10076614 CURRAX Nasal delivery devices
Oct, 2034

(11 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: NA

Dosage: POWDER;NASAL

More Information on Dosage

65. List of Oriahnn (copackaged) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10881659 ABBVIE INC Methods of treating heavy menstrual bleeding
Mar, 2034

(11 years from now)

US11045470 ABBVIE INC Methods of treating heavy menstrual bleeding
Mar, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 23, 2023
New Product (NP) May 29, 2023

Drugs and Companies using ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 29 May, 2020

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids)

Dosage: CAPSULE;ORAL

More Information on Dosage

66. List of Orilissa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11344551 ABBVIE INC Methods of treating heavy menstrual bleeding
Mar, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 23, 2023

Drugs and Companies using ELAGOLIX SODIUM ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 23 July, 2018

Treatment: Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women to reduce dysmenorrhea and non-menstrual pelvic pain; Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women having dyspareunia associated with endometriosis

Dosage: TABLET;ORAL

How can I launch a generic of ORILISSA before it's patent expiration?
More Information on Dosage

67. List of Otezla drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10092541 AMGEN INC Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
May, 2034

(11 years from now)

US9872854 AMGEN INC Methods for the treatment of psoriatic arthritis using apremilast
May, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 20, 2024
Orphan Drug Exclusivity (ODE) Jul 19, 2026
M Apr 10, 2023

Drugs and Companies using APREMILAST ingredient

Market Authorisation Date: 21 March, 2014

Treatment: Treatment of psoriasis using a dosage titration schedule; Treatment of adult patients with oral ulcers associated with behcet's disease using a dosage titration schedule; Treatment of psoriatic arthritis using a dosage titration schedule; Treatment of psoriatic arthritis with apremilast using a dosage titration schedule and a second active agent

Dosage: TABLET;ORAL

How can I launch a generic of OTEZLA before it's patent expiration?
More Information on Dosage

68. List of Oxbryta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248199 GLOBAL BLOOD THERAPS 1:1 adducts of sickle hemoglobin
Jan, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 25, 2024

Drugs and Companies using VOXELOTOR ingredient

NCE-1 date: November, 2023

Market Authorisation Date: 17 December, 2021

Treatment: Treatment of sickle cell disease by administering voxelotor, as recited in claim 1; Treatment of sickle cell disease by administering voxelotor, as recited in claim 2

Dosage: TABLET, FOR SUSPENSION;ORAL

More Information on Dosage

69. List of Oxlumo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11060093 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(11 years from now)

US10465195 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(11 years from now)

US9828606 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(11 years from now)

US10487330 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10435692 ALNYLAM PHARMS INC Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
Dec, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 23, 2027
New Chemical Entity Exclusivity (NCE) Nov 23, 2025
New Indication (I) Oct 6, 2025

Drugs and Companies using LUMASIRAN SODIUM ingredient

NCE-1 date: November, 2024

Market Authorisation Date: 23 November, 2020

Treatment: Treatment of primary hyperoxaluria type 1 (ph1)

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

70. List of Parsabiv drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9820938 KAI PHARMS INC Stable liquid formulation of AMG 416 (etelcalcetide)
Jun, 2034

(11 years from now)

US10344765 KAI PHARMS INC Stable liquid formulation of AMG 416 (etelcalcetide)
Jun, 2034

(11 years from now)

US11162500 KAI PHARMS INC Stable liquid formulation of AMG 416 (etelcalcetide)
Jun, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 7, 2022

Drugs and Companies using ETELCALCETIDE ingredient

NCE-1 date: February, 2021

Market Authorisation Date: 07 February, 2017

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of PARSABIV before it's patent expiration?
More Information on Dosage

71. List of Pluvicto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10398791 AAA USA NOVARTIS Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
Oct, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 23, 2027

Drugs and Companies using LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ingredient

NCE-1 date: March, 2026

Market Authorisation Date: 23 March, 2022

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

72. List of Procysbi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9173851 HORIZON Delayed release cysteamine bead formulation, and methods of making and using same
Jun, 2034

(11 years from now)

US9233077 HORIZON Delayed release cysteamine bead formulation, and methods of making and using same
Jun, 2034

(11 years from now)

US9173851

(Pediatric)

HORIZON Delayed release cysteamine bead formulation, and methods of making and using same
Dec, 2034

(11 years from now)

US9233077

(Pediatric)

HORIZON Delayed release cysteamine bead formulation, and methods of making and using same
Dec, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 22, 2024
Pediatric Exclusivity (PED) Feb 14, 2023

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Market Authorisation Date: 30 April, 2013

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of PROCYSBI before it's patent expiration?
More Information on Dosage

73. List of Procysbi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233077 HORIZON PHARMA USA Delayed release cysteamine bead formulation, and methods of making and using same
Jun, 2034

(11 years from now)

US9173851 HORIZON PHARMA USA Delayed release cysteamine bead formulation, and methods of making and using same
Jun, 2034

(11 years from now)

US9233077

(Pediatric)

HORIZON PHARMA USA Delayed release cysteamine bead formulation, and methods of making and using same
Dec, 2034

(11 years from now)

US9173851

(Pediatric)

HORIZON PHARMA USA Delayed release cysteamine bead formulation, and methods of making and using same
Dec, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 22, 2024
Pediatric Exclusivity (PED) Feb 14, 2023

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Market Authorisation Date: 14 February, 2020

Treatment: NA

Dosage: GRANULE, DELAYED RELEASE;ORAL

How can I launch a generic of PROCYSBI before it's patent expiration?
More Information on Dosage

74. List of Quviviq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9790208 IDORSIA Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
Dec, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10023560 IDORSIA Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
Dec, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 7, 2027

Drugs and Companies using DARIDOREXANT HYDROCHLORIDE ingredient

NCE-1 date: April, 2026

Market Authorisation Date: 07 April, 2022

Treatment: Treatment of insomnia

Dosage: TABLET;ORAL

More Information on Dosage

75. List of Rayaldee drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10357502 EIRGEN Stabilized modified release vitamin D formulation and method of administering same
Mar, 2034

(11 years from now)

US11253528 EIRGEN Stabilized modified release Vitamin D formulation and method of administering same
Mar, 2034

(11 years from now)

US9861644 EIRGEN Stabilized modified release vitamin D formulation and method of administering same
Mar, 2034

(11 years from now)

US10300078 EIRGEN Stabilized modified release vitamin D formulation and method of administering same
Mar, 2034

(11 years from now)

Drugs and Companies using CALCIFEDIOL ingredient

Market Authorisation Date: 17 June, 2016

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

76. List of Restasis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9676525 ALLERGAN Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids
Feb, 2034

(11 years from now)

US9669974 ALLERGAN Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids
May, 2034

(11 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 23 December, 2002

Treatment: NA

Dosage: EMULSION;OPHTHALMIC

How can I launch a generic of RESTASIS before it's patent expiration?
More Information on Dosage

77. List of Rhopressa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9931336 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US10588901 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US9415043 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11185538 AERIE PHARMS INC Compositions for treating glaucoma or reducing intraocular pressure
Mar, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2022

Drugs and Companies using NETARSUDIL MESYLATE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 18 December, 2017

Treatment: Reduction of elevated intraocular pressure

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of RHOPRESSA before it's patent expiration?
More Information on Dosage

78. List of Rocklatan drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9415043 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US9993470 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US9931336 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US10588901 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11197853 AERIE PHARMS INC Combination therapy
Mar, 2034

(11 years from now)

US11185538 AERIE PHARMS INC Compositions for treating glaucoma or reducing intraocular pressure
Mar, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 18, 2022
New Combination (NC) Mar 12, 2022

Drugs and Companies using LATANOPROST; NETARSUDIL DIMESYLATE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 12 March, 2019

Treatment: Reduction of elevated intraocular pressure

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ROCKLATAN before it's patent expiration?
More Information on Dosage

79. List of Ryaltris drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561672 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(11 years from now)

US11400101 GLENMARK SPECIALTY Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Sep, 2034

(11 years from now)

US10765686 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(11 years from now)

US10758550 GLENMARK SPECIALTY Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Sep, 2034

(11 years from now)

US10646500 GLENMARK SPECIALTY Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Sep, 2034

(11 years from now)

US10548907 GLENMARK SPECIALTY Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Sep, 2034

(11 years from now)

US10016443 GLENMARK SPECIALTY Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Sep, 2034

(11 years from now)

US10517880 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(11 years from now)

US9750754 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(11 years from now)

US9078923 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(11 years from now)

US9937189 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(11 years from now)

US10376526 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(11 years from now)

US9370483 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Jan 13, 2025

Drugs and Companies using MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 January, 2022

Treatment: Treatment of seasonal allergic rhinitis by nasaly administering a combination of olopatadine hydrochloride and mometasone furoate; Method of delivering a combination of olopatadine hydrochloride and mometasone furoate to a nasal airway; Treatment of seasonal allergic rhinitis by nasaly administering a combination of olopatadine hydrochloride and mometasone furoate to a pediatric patient

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

80. List of Rybelsus drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10278923 NOVO Oral dosing of GLP-1 compounds
May, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
M Jan 16, 2023
New Product (NP) Sep 20, 2022
New Chemical Entity Exclusivity (NCE) Dec 5, 2022

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 20 September, 2019

Treatment: Method of treating type 2 diabetes mellitus

Dosage: TABLET;ORAL

More Information on Dosage

81. List of Sinuva drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10406332 INTERSECT ENT INC Systems, devices, and method for treating a sinus condition
Mar, 2034

(11 years from now)

US10232152 INTERSECT ENT INC Systems, devices, and method for treating a sinus condition
Nov, 2034

(11 years from now)

Drugs and Companies using MOMETASONE FUROATE ingredient

Market Authorisation Date: 08 December, 2017

Treatment: Treatment of nasal polyps in patients >=18 years of age who have had ethmoid sinus surgery using a corticosteroid-eluting (mometasone furoate) implant

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage

82. List of Soolantra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233118 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(11 years from now)

US9089587 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(11 years from now)

US9233117 GALDERMA LABS LP Treatment of inflammatory lesions of rosacea with ivermectin
Mar, 2034

(11 years from now)

US9782425 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(11 years from now)

US10206939 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(11 years from now)

Drugs and Companies using IVERMECTIN ingredient

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of inflammatory lesions of rosacea.

Dosage: CREAM;TOPICAL

How can I launch a generic of SOOLANTRA before it's patent expiration?
More Information on Dosage

83. List of Sotylize drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11013703 AZURITY Sotalol compositions and uses of the same
Apr, 2034

(11 years from now)

US10206895 AZURITY Sotalol compositions and uses of the same
Apr, 2034

(11 years from now)

Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient

Market Authorisation Date: 22 October, 2014

Treatment: Sotylize is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently in sinus rhythm; Indicated for the treatment of ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgement of the physician are life-threatening

Dosage: SOLUTION;ORAL

More Information on Dosage

84. List of Spinraza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9926559 BIOGEN IDEC Compositions and methods for modulation of SMN2 splicing in a subject
Jan, 2034

(10 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 23, 2023

Drugs and Companies using NUSINERSEN SODIUM ingredient

Market Authorisation Date: 23 December, 2016

Treatment: Treatment of spinal muscular atrophy

Dosage: SOLUTION;INTRATHECAL

More Information on Dosage

85. List of Spravato drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446260 JANSSEN PHARMS Pharmaceutical composition of S-ketamine hydrochloride
Mar, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 5, 2024
New Indication (I) Jul 31, 2023

Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 March, 2019

Treatment: Treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally administering 56mg or 84mg of esketamine as a pharmaceutical composition twice per week in conjunction with an oral antidepressant; Treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketamine twice per week as a pharmaceutical composition in conjunction with an oral antidepressant; Treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketamine as a pharmaceutical composition in conjunction with an oral antidepressant

Dosage: SPRAY;NASAL

More Information on Dosage

86. List of Spritam drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11160786 APRECIA PHARMS Rapid disperse dosage form
Mar, 2034

(11 years from now)

US9669009 APRECIA PHARMS Rapid disperse dosage form containing levetiracetam
Mar, 2034

(11 years from now)

US9339489 APRECIA PHARMS Rapid disperse dosage form containing levetiracetam
Mar, 2034

(11 years from now)

Drugs and Companies using LEVETIRACETAM ingredient

Market Authorisation Date: 31 July, 2015

Treatment: Method of administering levetiracetam under fasted conditions; Method of administering levetiracetam; Method of administering levetiracetam under fed conditions

Dosage: TABLET, FOR SUSPENSION;ORAL

More Information on Dosage

87. List of Sunosi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11439597 AXSOME MALTA Formulations of (R)-2-amino-3-phenylpropyl carbamate
Nov, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

88. List of Synjardy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 26 August, 2015

Treatment: Method of treating type 2 diabetes mellitus in a patent with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr<30 ml/min/1.73 m2; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin

Dosage: TABLET;ORAL

How can I launch a generic of SYNJARDY before it's patent expiration?
More Information on Dosage

89. List of Synjardy Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 09 December, 2016

Treatment: Method of treating type 2 diabetes mellitus in a patent with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr<30 ml/min/1.73 m2; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of SYNJARDY XR before it's patent expiration?
More Information on Dosage

90. List of Talicia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9050263 REDHILL Pharmaceutical compositions for the treatment of Helicobacter pylori
Feb, 2034

(11 years from now)

US11135172 REDHILL Rifabutin-based compositions and methods for treating Helicobacter pylori infection
Feb, 2034

(11 years from now)

US9498445 REDHILL Pharmaceutical compositions for the treatment of Helicobacter pylori
Feb, 2034

(11 years from now)

US10238606 REDHILL Pharmaceutical compositions for the treatment of Helicobacter pylori
Feb, 2034

(11 years from now)

US9603806 REDHILL Pharmaceutical compositions for the treatment of Helicobacter pylori
Feb, 2034

(11 years from now)

Drugs and Companies using AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN ingredient

Market Authorisation Date: 01 November, 2019

Treatment: Treatment of h. pylori infection in adults

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage

91. List of Tazverik drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8410088 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Aug, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9688665 EPIZYME INC Methods of treating cancer
Aug, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 23, 2025
New Indication (I) Jun 18, 2023
Orphan Drug Exclusivity (ODE) Jan 23, 2027

Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient

NCE-1 date: January, 2024

Market Authorisation Date: 23 January, 2020

Treatment: Method of treating epithelioid sarcoma

Dosage: TABLET;ORAL

More Information on Dosage

92. List of Tembexa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8962829 CHIMERIX Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof
Oct, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10112909 CHIMERIX Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof
Oct, 2034

(11 years from now)

US10487061 CHIMERIX Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof
Oct, 2034

(11 years from now)

US9371344 CHIMERIX Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof
Oct, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Jun 4, 2024
Orphan Drug Exclusivity (ODE) Jun 4, 2028

Drugs and Companies using BRINCIDOFOVIR ingredient

Market Authorisation Date: 04 June, 2021

Treatment: Method of treating human smallpox disease

Dosage: TABLET;ORAL

More Information on Dosage

93. List of Trijardy Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(11 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 January, 2020

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin, linagliptin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr <30 ml/min/1.73 m2; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin in combination with linagliptin and metformin

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of TRIJARDY XR before it's patent expiration?
More Information on Dosage

94. List of Trulance drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10011637 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Jun, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11142549 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Jun, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 19, 2022

Drugs and Companies using PLECANATIDE ingredient

NCE-1 date: January, 2021

Market Authorisation Date: 19 January, 2017

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of TRULANCE before it's patent expiration?
More Information on Dosage

95. List of Truseltiq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11160804 HELSINN HLTHCARE Pharmaceutical dosage forms
Dec, 2034

(11 years from now)

US10278969 HELSINN HLTHCARE Pharmaceutical dosage forms
Dec, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 28, 2026
Orphan Drug Exclusivity (ODE) May 28, 2028

Drugs and Companies using INFIGRATINIB PHOSPHATE ingredient

NCE-1 date: May, 2025

Market Authorisation Date: 28 May, 2021

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

96. List of Velphoro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11234938 VIFOR FRESENIUS Pharmaceutical composition, comprising phosphate binder particles
Nov, 2034

(11 years from now)

US11446252 VIFOR FRESENIUS Pharmaceutical composition, comprising phosphate binder particles
Nov, 2034

(11 years from now)

US10624855 VIFOR FRESENIUS Pharmaceutical composition, comprising phosphate binder particles
Nov, 2034

(11 years from now)

Drugs and Companies using FERRIC OXYHYDROXIDE ingredient

Market Authorisation Date: 27 November, 2013

Treatment: NA

Dosage: TABLET, CHEWABLE;ORAL

More Information on Dosage

97. List of Vogelxo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9295675 UPSHER SMITH LABS Testosterone gel compositions and related methods
Feb, 2034

(11 years from now)

US9662340 UPSHER SMITH LABS Testosterone gel compositions and related methods
Feb, 2034

(11 years from now)

US8785426 UPSHER SMITH LABS Testosterone gel compositions and related methods
Feb, 2034

(11 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 04 June, 2014

Treatment: Method for transdermal delivery of testosterone

Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL

More Information on Dosage

98. List of Vosevi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9296782 GILEAD SCIENCES INC Inhibitors of hepatitis C virus
Jul, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11116783 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(11 years from now)

US11116783

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 18, 2022

Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient

NCE-1 date: July, 2021

Market Authorisation Date: 18 July, 2017

Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor; Treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor

Dosage: TABLET;ORAL

More Information on Dosage

99. List of Vyxeos drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028912 CELATOR PHARMS Method of lyophilizing liposomes
Sep, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 3, 2024
New Patient Population (NPP) Mar 30, 2024

Drugs and Companies using CYTARABINE; DAUNORUBICIN ingredient

Market Authorisation Date: 03 August, 2017

Treatment: Method of administering a reconstituted liposomal composition containing cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older; Method of reconstituting a lyophilized liposomal composition for administering cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

100. List of Welireg drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9969689 MERCK SHARP DOHME Aryl ethers and uses thereof
Sep, 2034

(11 years from now)

US9908845 MERCK SHARP DOHME Aryl ethers and uses thereof
Sep, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 13, 2026
Orphan Drug Exclusivity (ODE) Aug 13, 2028

Drugs and Companies using BELZUTIFAN ingredient

NCE-1 date: August, 2025

Market Authorisation Date: 13 August, 2021

Treatment: Treatment of adult patients with von hippel-lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery

Dosage: TABLET;ORAL

More Information on Dosage

101. List of Xarelto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539218 JANSSEN PHARMS Prevention and treatment of thromboembolic disorders
Feb, 2034

(11 years from now)

US9539218

(Pediatric)

JANSSEN PHARMS Prevention and treatment of thromboembolic disorders
Aug, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Aug 23, 2024
M Mar 10, 2023
Pediatric Exclusivity (PED) Apr 11, 2023

Drugs and Companies using RIVAROXABAN ingredient

Market Authorisation Date: 01 July, 2011

Treatment: Treatment of pulmonary embolism with once daily, rapid-release tablet administered for at least five consecutive days; Treatment of deep vein thrombosis with once daily, rapid-release tablet administered for at least five consecutive days; Prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery, with once daily, rapid-release tablet administered for at least five consecutive days; Reduce the risk of stroke in patients with nonvalvular atrial fibrillation with once daily, rapid-release tablet administered for at least five consecutive days; Prophylaxis of venous thromboembolism in acutely ill medical patients at risk for thromboembolic complications not at high risk of bleeding with once daily, rapid-release tablet administered for at least 5 consecutive days; Treatment of dvt and/or pe and reduction in the risk of recurrent dvt and/or pe in pediatric patients (>=50 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment; After completion of initial treatment lasting at least 6 months, to reduce the risk of recurrence of deep vein thrombosis and/or pulmonary embolism in certain patients with once daily, rapid-release tablet administered for at least 5 consecutive days; Prophylaxis of pe, dvt and/or stroke in pediatric patients (>=50 kg) aged 2 years and older with congenital heart disease after fontan procedure with once daily, rapid-release tablet administered for at least 5 consecutive days; Treatment of dvt and/or pe and reduction in risk of recurrent dvt and/or pe in pediatric patients (30-49.9 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment

Dosage: TABLET;ORAL

How can I launch a generic of XARELTO before it's patent expiration?
More Information on Dosage

102. List of Xeglyze drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10292389 DR REDDYS LABS SA Pediculicidal composition
Dec, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 24, 2025

Drugs and Companies using ABAMETAPIR ingredient

NCE-1 date: July, 2024

Market Authorisation Date: 24 July, 2020

Treatment: Topical treatment of head lice infestation in patients 6 months of age and older

Dosage: LOTION;TOPICAL

More Information on Dosage

103. List of Xeljanz Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10639309 PFIZER Tofacitinib oral sustained release dosage forms
Mar, 2034

(11 years from now)

US9937181 PFIZER Tofacitinib oral sustained release dosage forms
Mar, 2034

(11 years from now)

US11253523 PFIZER Tofacitinib oral sustained release dosage forms
Mar, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 14, 2024

Drugs and Companies using TOFACITINIB CITRATE ingredient

Market Authorisation Date: 23 February, 2016

Treatment: A method of treating ankylosing spondylitis by administering the formulation of tofacitinib of claims 1, 8, 15-20, 27-31, 34-43, 45, 47, 49, 50, 54, 59, 63, 68-71, 73, 77, 82-84, and 87-98; A method of treating psoriatic arthritis by administering the formulation of tofacitinib of claims 1, 8, 15-20, 27-31, 34-44, 46, 48, 50, 53, 59, 62, 68-71, 73, 76, 82-84, and 87-98; A method of treating rheumatoid arthritis by administering the formulation of tofacitinib of claims 1, 2, 8, 9, 15-21, 27-31, 34-43, 50, 51, 59, 60, 68-71, 73, 74, 82-84 and 87-98; A method of treating ulcerative colitis, by administering the formulation of tofacitinib of claims 1, 3, 8, 10, 15-20, 22, 27-31, 34-43, 50, 52, 59, 61, 68-71, 73, 75, 82-84 and 87-98

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of XELJANZ XR before it's patent expiration?
More Information on Dosage

104. List of Xhance drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10076614 OPTINOSE US INC Nasal delivery devices
Oct, 2034

(11 years from now)

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 18 September, 2017

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

105. List of Xipere drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9937075 BAUSCH AND LOMB INC Apparatus and methods for ocular injection
May, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Oct 22, 2024

Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient

Market Authorisation Date: 22 October, 2021

Treatment: NA

Dosage: SUSPENSION;INJECTION

More Information on Dosage

106. List of Xyosted (autoinjector) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10881798 ANTARES PHARMA INC Needle assisted injection device having reduced trigger force
Feb, 2034

(11 years from now)

US11160751 ANTARES PHARMA INC Hematocrit modulation through needle assisted jet injection of testosterone
Oct, 2034

(11 years from now)

Drugs and Companies using TESTOSTERONE ENANTHATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Method of administering testosterone enanthate subcutaneously

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

107. List of Yonsa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9889144 SUN PHARM Abiraterone acetate formulation and methods of use
Mar, 2034

(11 years from now)

US10292990 SUN PHARM Abiraterone steroid formulation
May, 2034

(11 years from now)

Drugs and Companies using ABIRATERONE ACETATE ingredient

Market Authorisation Date: 22 May, 2018

Treatment: Use in combination with methylprednisolone for the treatment of patients with prostate cancer

Dosage: TABLET;ORAL

How can I launch a generic of YONSA before it's patent expiration?
More Information on Dosage

108. List of Zerbaxa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8906898 CUBIST PHARMS LLC Solid forms of ceftolozane
May, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11278622 CUBIST PHARMS LLC Ceftolozane antibiotic compositions
Mar, 2034

(11 years from now)

US8968753 CUBIST PHARMS LLC Ceftolozane-tazobactam pharmaceutical compositions
Mar, 2034

(11 years from now)

US10420841 CUBIST PHARMS LLC Ceftolozane antibiotic compositions
Mar, 2034

(11 years from now)

US9872906 CUBIST PHARMS LLC Ceftolozane antibiotic compositions
Mar, 2034

(11 years from now)

US9320740 CUBIST PHARMS LLC Ceftolozane-tazobactam pharmaceutical compositions
Mar, 2034

(11 years from now)

US10933053 CUBIST PHARMS LLC Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
Sep, 2034

(11 years from now)

US10376496 CUBIST PHARMS LLC Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
Sep, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 19, 2019
New Patient Population (NPP) Apr 21, 2025
Generating Antibiotic Incentives Now (GAIN) Dec 19, 2024

Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient

NCE-1 date: December, 2023

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of hospital-acquired bacterial pneumonia (habp); Treatment of ventilator-associated bacterial pneumonia (vabp); Treatment of complicated urinary tract infection, including pyelonephritis; Treatment of complicated intra-abdominal infection; Treatment of complicated urinary tract infection; Treatment of ventilator-associated bacterial pneumonia in patients with end-stage renal disease on hemodialysis; Treatment of hospital-acquired bacterial pneumonia in patients with end-stage renal disease on hemodialysis; Treatment of complicated urinary tract infection in patients with end-stage renal disease on hemodialysis; Treatment of complicated intra-abdominal infection in patients with end-stage renal disease on hemodialysis

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

109. List of Zohydro Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9713611 RECRO GAINESVILLE Abuse resistant pharmaceutical compositions
Sep, 2034

(11 years from now)

US9452163 RECRO GAINESVILLE Abuse resistant pharmaceutical compositions
Sep, 2034

(11 years from now)

US9486451 RECRO GAINESVILLE Abuse resistant pharmaceutical compositions
Sep, 2034

(11 years from now)

US10092559 RECRO GAINESVILLE Abuse resistant pharmaceutical compositions
Sep, 2034

(11 years from now)

US9132096 RECRO GAINESVILLE Abuse resistant pharmaceutical compositions
Sep, 2034

(11 years from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Market Authorisation Date: 25 October, 2013

Treatment: Treatment of pain

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of ZOHYDRO ER before it's patent expiration?
More Information on Dosage

110. List of Zuragard drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10688291 ZUREX PHARMA Medical skin applicator apparatus
Dec, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Apr 26, 2022
M Jun 24, 2024

Drugs and Companies using ISOPROPYL ALCOHOL ingredient

Market Authorisation Date: 26 April, 2019

Treatment: Use as an antiseptic for the preparation of a patient's skin prior to surgery

Dosage: SOLUTION;TOPICAL

More Information on Dosage

111. List of Zynrelef Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9913909 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent
Mar, 2034

(11 years from now)

US11253504 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent
Mar, 2034

(11 years from now)

US10398686 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent
Mar, 2034

(11 years from now)

US9744163 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent
Mar, 2034

(11 years from now)

US9592227 HERON THERAPS INC Compositions of a polyorthoester and an aprotic solvent
Mar, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) May 12, 2024

Drugs and Companies using BUPIVACAINE; MELOXICAM ingredient

Market Authorisation Date: 12 May, 2021

Treatment: Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarticular instillation

Dosage: SOLUTION, EXTENDED RELEASE;PERIARTICULAR

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

List of large molecules

1. List of Lucentis large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US9765379 GENENTECH, INC. Harvest operations for recombinant proteins
Mar, 2034

(11 years from now)

US10829732 GENENTECH, INC. Cell culture compositions with antioxidants and methods for polypeptide production
Mar, 2034

(11 years from now)

US10017732 GENENTECH, INC. Cell culture compositions with antioxidants and methods for polypeptide production
Mar, 2034

(11 years from now)

Ingredients: RANIBIZUMAB

2. List of Humira large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US9499614 ABBVIE INC. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
Mar, 2034

(11 years from now)

US9550826 ABBVIE INC. Glycoengineered binding protein compositions
Nov, 2034

(11 years from now)

Ingredients: ADALIMUMAB

3. List of Avastin large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US10676710 GENENTECH, INC. Cell culture compositions with antioxidants and methods for polypeptide production
Mar, 2034

(11 years from now)

US9441035 GENENTECH, INC. Cell culture media and methods of antibody production
Apr, 2034

(11 years from now)

Ingredients: BEVACIZUMAB

4. List of Eylea large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US11332771 REGENERON PHARMACEUTICALS, INC. Serum-free cell culture medium
Mar, 2034

(11 years from now)

USD858754 REGENERON PHARMACEUTICALS, INC. Syringe cap
Sep, 2034

(11 years from now)

Ingredients: AFLIBERCEPT

5. List of Tysabri large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US10677803 BIOGEN INC. Method of assessing risk of PML
May, 2034

(11 years from now)

US11280794 BIOGEN INC. Method of assessing risk of PML
May, 2034

(11 years from now)

US10119976 BIOGEN INC. Method of assessing risk of PML
May, 2034

(11 years from now)

US10676772 BIOGEN INC. Control of protein glycosylation by culture medium supplementation and cell culture process parameters
Aug, 2034

(11 years from now)

US9994968 BIOGEN INC. Electrochemical etching apparatus
Aug, 2034

(11 years from now)

Ingredients: NATALIZUMAB

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in